Gyre Therapeutics (GYRE) Assets (2010 - 2026)
Gyre Therapeutics (GYRE) reported Assets of $162.0 million for Q1 2026, up 24.83% year-over-year from $129.8 million in Q1 2025, and down 2.48% on a QoQ basis from $166.1 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Assets data on file, last reported at $162.0 million in Q1 2026.
- Quarterly Assets rose 24.83% year-over-year to $162.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $162.0 million (up 24.83% YoY) and the FY2025 annual result came in at $166.1 million, up 32.48% from the prior year.
- Assets retreated to $162.0 million in Q1 2026 per GYRE's latest filing, from $166.1 million in the prior quarter.
- Across five years, Assets topped out at $166.1 million in Q4 2025 and bottomed at $10.0 million in Q3 2023.
- The 5-year median for Assets is $120.9 million (2024), against an average of $97.7 million.
- The widest annual swing landed in 2023, when Assets sank 85.13%; it then soared 1156.92% in 2024.
- Tracing GYRE's Assets over 5 years: stood at $84.8 million in 2022, then surged by 37.5% to $116.5 million in 2023, then rose by 7.61% to $125.4 million in 2024, then jumped by 32.48% to $166.1 million in 2025, then slipped by 2.48% to $162.0 million in 2026.
- Per Business Quant, the three latest GYRE Assets figures stand at $162.0 million (Q1 2026), $166.1 million (Q4 2025), and $159.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 162.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.02 Mn |
| Dec 31, 2025 | 166.13 Mn |
| Sep 30, 2025 | 159.38 Mn |
| Jun 30, 2025 | 152.65 Mn |
| Mar 31, 2025 | 129.79 Mn |
| Dec 31, 2024 | 125.41 Mn |
| Sep 30, 2024 | 125.24 Mn |
| Jun 30, 2024 | 120.93 Mn |
| Mar 31, 2024 | 122.01 Mn |
| Dec 31, 2023 | 116.54 Mn |
| Sep 30, 2023 | 9.96 Mn |
| Jun 30, 2023 | 12.39 Mn |
| Mar 31, 2023 | 18.75 Mn |
| Dec 31, 2022 | 84.75 Mn |
| Sep 30, 2022 | 31.02 Mn |
| Jun 30, 2022 | 83.37 Mn |
| Mar 31, 2022 | 40.27 Mn |
| Dec 31, 2021 | 55.66 Mn |
| Sep 30, 2021 | 78.54 Mn |
| Jun 30, 2021 | 101.79 Mn |
| Mar 31, 2021 | 119.08 Mn |
| Dec 31, 2020 | 94.85 Mn |
| Sep 30, 2020 | 111.80 Mn |
| Jun 30, 2020 | 123.68 Mn |
| Mar 31, 2020 | 110.56 Mn |
| Dec 31, 2019 | 98.55 Mn |
| Sep 30, 2019 | 91.79 Mn |
| Jun 30, 2019 | 100.87 Mn |
| Mar 31, 2019 | 111.87 Mn |
| Dec 31, 2018 | 124.92 Mn |
| Sep 30, 2018 | 133.42 Mn |
| Jun 30, 2018 | 139.54 Mn |
| Mar 31, 2018 | 145.89 Mn |
| Dec 31, 2017 | 39.51 Mn |
| Sep 30, 2017 | 34.39 Mn |
| Jun 30, 2017 | 39.63 Mn |
| Mar 31, 2017 | 29.06 Mn |
| Dec 31, 2016 | 38.09 Mn |
| Sep 30, 2016 | 51.62 Mn |
| Jun 30, 2016 | 57.22 Mn |
| Mar 31, 2016 | 61.54 Mn |
| Dec 31, 2015 | 69.52 Mn |
| Sep 30, 2015 | 74.51 Mn |
| Jun 30, 2015 | 101.17 Mn |
| Mar 31, 2015 | 107.14 Mn |
| Dec 31, 2014 | 2.98 Mn |
| Sep 30, 2014 | 116.12 Mn |
| Jun 30, 2014 | 124.52 Mn |
| Mar 31, 2014 | 134.11 Mn |
| Dec 31, 2013 | 145.87 Mn |
| Sep 30, 2013 | 157.85 Mn |
| Jun 30, 2013 | 167.49 Mn |
| Mar 31, 2013 | 178.75 Mn |
| Dec 31, 2012 | 189.58 Mn |
| Sep 30, 2012 | 203.50 Mn |
| Jun 30, 2012 | 212.62 Mn |
| Mar 31, 2012 | 231.10 Mn |
| Dec 31, 2011 | 258.13 Mn |
| Sep 30, 2011 | 279.74 Mn |
| Jun 30, 2011 | 300.02 Mn |
| Dec 31, 2010 | 262.79 Mn |